Bile Duct Neoplasms (Bile Duct Cancer)

11/01/2015 - "Twenty-nine patients (median 71 [range 47-88] years) with nonresectable hilar bile duct cancer were treated with T-PDT (median 1 [range 1-4] sessions) plus stenting and followed up every 3 months. "
03/01/2012 - "Higher T-stage appears to be a predictor of early mortality in advanced bile duct cancer treated with PDT."
01/01/2008 - "In some case reports and small non-randomized pilot studies, PDT has proved feasible in patients with hilar bile duct cancer. "
12/01/2001 - "Four patients with nonresectable bile duct cancer underwent cholangiography, cholangioscopy, and intraductal US before PDT. "
12/01/2001 - "Therefore the feasibility of PDT was investigated for nonresectable bile duct cancer by using 5-aminolevulinic acid. "

11/01/2015 - "[A Long-Term Survival Case of Unresectable Hilar Bile Duct Cancer Treated with Gemcitabine]."
11/01/2015 - "The patient was treated with gemcitabine as systemic chemotherapy for unresectable hilar bile duct cancer. "
02/01/2013 - "[A case of inoperable advanced bile duct cancer treated effectively with combined chemotherapy of gemcitabine and S-1]."
08/01/2010 - "[Response in a case of inoperable bile duct cancer treated by combined chemotherapy of S-1 and gemcitabine]."
10/01/2009 - "[A case of unresectable hilar bile duct cancer responding to chemo-radiotherapy by gemcitabine]."

06/01/2013 - "Photodynamic therapy for hilar bile duct cancer: clinical evidence for improved tumoricidal tissue penetration by temoporfin."
06/01/2007 - "This study investigates the photodynamic characteristics of mTHPC in solvent-based formulation (Foscan) and in liposomal (water soluble) formulation (Foslip) in an in vitro model system consisting of two biliary cancer cell lines (GBC, gall bladder cancer and BDC, bile duct cancer cells). "
11/01/2015 - "Temoporfin-PDT can safely be delivered to hilar bile duct cancer patients and results in prolonged patency of hilar bile ducts, a trend for longer survival time, and similar palliation as with P-PDT. "

11/01/2013 - "Tumoricidal efficacy of simvastatin and S-1 was further investigated in a subcutaneous bile duct cancer model in NOD/SCID mice. "
11/01/2013 - "Simvastatin enhances the chemotherapeutic efficacy of S-1 against bile duct cancer: E2F-1/TS downregulation might be the mechanism."
11/01/2013 - "The present study aimed to investigate the interactive effects between simvastatin and S-1 against bile duct cancer and its mechanisms. "
11/01/2013 - "Simvastatin and S-1 exerted synergistic effects against bile duct cancer, which might be mediated by E2F-1/TS downregulation. "
11/01/2013 - "Simvastatin enhanced the cytotoxicity of 5-FU on bile duct cancer cells in vitro. "

09/21/2007 - "After 28 d, NVP-LBH589 significantly reduced tumor mass by 66% (bile duct cancer) and 87% (gallbladder cancer) in vivo in comparison to placebo, and potentiated the efficacy of gemcitabine. "

01/01/2012 - "This study may be helpful to the potential use of curcumin as a treatment for bile duct cancer, and to understanding the genetic polymorphism of Mrp2 for clinical trials of curcumin."
08/01/2010 - "Redox modulation and human bile duct cancer inhibition by curcumin."
08/01/2010 - "The study was to clarify effects of curcumin on cholangiocarcinoma cells, a cancer of the bile duct that refractory to chemotherapeutic drugs. "

06/01/1988 - "This case suggested the activity of 5-FU, ADM and MMC combination for bile duct cancer."
05/01/2000 - "In particular, 5-fluorouracil has been a component of most chemotherapy regimens for bile duct cancer. "
08/01/1986 - "[Intraductal chemotherapy of bile duct cancer with 5-fluorouracil]."
02/01/1999 - "The purpose of the present study was to evaluate the cellular sensitivity of Mz-ChA-2 (derived from gall bladder cancer) and SK-ChA-1 (derived from bile duct cancer) to 5-FU. "
01/01/2011 - "Twenty three patients with non-metastatic bile duct cancer treated surgically with curative intent (4 gallbladder, 7 ampullary and 12 cholangiocarcinoma) received 3D conformal external beam RT to a median total dose of 50.4 Gy. Concurrent chemotherapy based on 5-FU was delivered to 21 patients (91%). "

06/01/2006 - "Our results suggest that a common PTGS2 variant increases bile duct cancer risk. "
03/01/2004 - "Different expression of cyclooxygenase-2 in biliary epithelia of bile duct cancer with or without pancreaticobiliary maljunction."
10/01/2001 - "Differential expression of cyclooxygenase-2 (COX-2) in human bile duct epithelial cells and bile duct neoplasm."
09/01/2006 - "Using data from the Shanghai Biliary Tract Cancer Study, the advantages of the newly proposed omnibus test were apparent in a population-based study of bile duct cancer and polymorphisms in the prostaglandin-endoperoxide synthase 2 (PTGS2) gene."
03/01/2011 - "Protease-activated receptor-2 regulates cyclooxygenase-2 expression in human bile duct cancer via the pathways of mitogen-activated protein kinases and nuclear factor kappa B."

09/01/2004 - "Carbohydrate antigen 19-9 was elevated as 112.1 U/mL. Operative findings included a resectable left hilar bile duct cancer and grayish-white nodules 0.3-0.5cm in diameter on the surface of segments 6 and 4 of the liver. "
07/01/2004 - "A typical marker of pancreatic and bile duct cancer is carbohydrate antigen, but the sensitivity of these markers is only 50%. "
01/01/1999 - "In the present study, we compared the serum level of STn antigen in 14 patients with benign diseases of the biliary tract and pancreas, 15 patients with bile duct cancers, and 9 patients with cancer of the pancreas. "
11/01/2013 - "Preoperative elevated carbohydrate antigen 19-9 (CA 19-9) level (P = 0.006), positive resection margin (P < 0.001), advanced T stage (P = 0.043), and lymph node metastasis (P = 0.002) were significantly independent worse prognostic indicators by multivariate analysis of resectable distal bile duct cancer. "
05/01/1991 - "Accordingly, it was thought necessary to investigate a change of cut off value and reevaluate CA 19-9 for pancreatic cancer and bile duct cancer in comparison with other tumor markers of carbohydrate antigen such as CA 50, sialyl SSEA-1. "

06/01/1993 - "This study was designed to elucidate the role of the expression of NCAM on the development of perineural invasion in bile duct cancer. "
01/01/1998 - "The binding activity of the conjugate to the NCAM-positive bile duct cancer was examined by immunohistochemical staining and proved to be the same level as that of free anti-NCAM MoAb. "
02/01/1995 - "However, the perineural invasion of negative cells in NCAM expression is not likely to occur as compared to bile duct cancer. "
06/01/1993 - "These results highlight an important role of NCAM in the development of perineural invasion in bile duct cancer."
06/01/1993 - "A significant positive correlation was found between the expression of NCAM and perineural invasion in bile duct cancer. "

01/01/2008 - "There is an RCT demonstrating that, in unresectable bile duct cancer, extended survival and improved quality of life (QOL) have been achieved through a combination of photodynamic therapy and biliary stenting, compared with biliary stenting alone. "
11/01/2005 - "Palliation of nonresectable bile duct cancer: improved survival after photodynamic therapy."
02/01/2000 - "Photodynamic therapy for advanced bile duct cancer: evidence for improved palliation and extended survival."
01/01/2013 - "Current status of photodynamic therapy for bile duct cancer."
05/01/2005 - "Prospective study of the effectiveness of percutaneous transhepatic photodynamic therapy for advanced bile duct cancer and the role of intraductal ultrasonography in response assessment."

02/01/1985 - "Improvement in the survival of patients with cancer of the bile duct probably depends on development of better adjuvant therapy, such as new techniques of radiation therapy and new modalities of chemotherapy, in association with surgery or with a percutaneous or endoscopic intubation technique."
07/01/2015 - "The aim of this study was to determine if a decline in CA19-9 (CA19-9 response) during chemotherapy is predictive of survival in patients with inoperable bile duct cancer. "
07/01/2015 - "However, the value of serum CA19-9 as a biomarker of response to chemotherapy in bile duct cancer is unclear. "
07/01/2015 - "Decline in CA19-9 during chemotherapy predicts survival in four independent cohorts of patients with inoperable bile duct cancer."
11/01/2012 - "Recently, the DBE has enabled systemic chemotherapy to be started after obtaining pathological evidence of malignancy, as well as biliary drainage instead of percutaneous transhepatic biliary drainage in cases with recurrent bile duct cancers. "

05/01/1992 - "[Improved treatment results in advanced gallbladder and bile duct cancer by postoperative combined radiotherapy]."
10/01/1996 - "The purpose of this study was to assess the feasibility and morbidity of accelerated external beam radiotherapy with or without intraluminal radiotherapy in the treatment of locally advanced bile duct cancer. "
03/01/2014 - "To evaluate the results of postoperative radiotherapy in patients with extra-hepatic bile duct cancer (EHBDC) and identify the prognostic factors for local control and survival. "
03/01/2014 - "Postoperative radiotherapy dose correlates with locoregional control in patients with extra-hepatic bile duct cancer."
01/01/2010 - "To establish a method of quantitative assessment of the duodenal exposure dose to avoid duodenal morbidity after radiotherapy for bile duct cancer. "

01/01/2014 - "To determine the clinical efficacy of metallic biliary stents combined with different anticancer treatments in the management of bile duct cancer. "
09/01/2014 - "In hilar bile duct cancer, unilateral and bilateral stents showed similar liver volume increases (20.1% and 25.8%, respectively; P = .512). "
09/01/2014 - "Stenting in hilar bile duct cancer tended to increase liver volume more than distal biliary stents (22.5% vs 11.9%, P = .091). "
09/01/2014 - "There were 60 patients; 31 were treated for hilar bile duct cancer (13 for bilateral stent and 18 for unilateral stent) and 29 for distal bile duct cancer. "
09/01/2014 - "We aimed to use volumetry to analyze liver volume changes after endoscopic stenting in bile duct cancer according to the location and number of stents. "

03/01/2003 - "This quality control study investigated whether parenchyma-preserving hepatectomy is a "noble option" in the surgical treatment of hilar bile duct cancer. "
12/01/2015 - "In the bile duct cancer group, FRL volume was 33.9 ± 2.2 % before PVE, 38.4 ± 1.5 % before HVE, 43.7 ± 2.1 % at surgery, and 73.6 ± 8.3 % at 2 weeks after right hepatectomy. "
03/01/2015 - "Hilar bile duct cancer was initially diagnosed and percutaneous transhepatic portal vein embolization was performed, preceding a planned right hepatectomy. "
09/01/2011 - "The patient underwent an extended left hepatectomy, and the resected specimen showed early bile duct cancer confined to the ductal mucosa."
07/01/2008 - "Modified liver hanging maneuver to facilitate left hepatectomy and caudate lobe resection for hilar bile duct cancer."